Comparative Pharmacology
Head-to-head clinical analysis: EC NAPROSYN versus FENOPROFEN CALCIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EC NAPROSYN versus FENOPROFEN CALCIUM.
EC-NAPROSYN vs FENOPROFEN CALCIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes, thereby reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, thereby exerting analgesic, anti-inflammatory, and antipyretic effects.
500-1000 mg orally twice daily; maximum 1500 mg/day.
Oral: 300-600 mg every 6-8 hours as needed; maximum 3200 mg/day.
None Documented
None Documented
Terminal elimination half-life 12-17 hours (mean 14 hours); prolonged in elderly and renal impairment
Terminal elimination half-life is 2–3 hours; may be prolonged in elderly and patients with hepatic impairment.
Renal (95%) as unchanged drug (10%) and conjugated metabolites (60%) and other metabolites (25%); biliary/fecal (5%)
Primarily renal; approximately 90% of a dose is excreted in urine as glucuronide conjugates and unchanged drug; <2% excreted in feces.
Category C
Category C
NSAID
NSAID